BeiGene

+$0.08 (+0.03%) Today
$0.00 (0.00%) As of 10:54 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BeiGene and other ETFs, options, and stocks.

About BGNE

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).

CEO
John V. Oyler
Employees
5,300
Headquarters
Beijing, Beijing
Founded
2010

BGNE Key Statistics

Market cap
28.60B
Price-Earnings ratio
—
Dividend yield
—
Average volume
255.57K
High today
$254.05
Low today
$243.88
Open price
$247.00
Volume
310.08K
52 Week high
$426.56
52 Week low
$220.04

BGNE News

Simply Wall StJan 20

What Percentage Of BeiGene, Ltd. Shares Do Insiders Own?

If you want to know who really controls BeiGene, Ltd. ( ), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows,

BGNE Earnings

-$5.23
-$3.26
-$1.28
$0.69
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Estimated
— per share
Actual
Expected Feb 24
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure